MBOT Overzicht aandelen Microbot Medical Inc., een preklinisch bedrijf voor medische apparatuur, houdt zich bezig met onderzoek, ontwerp en ontwikkeling van endoluminale chirurgische robotapparaten voor minimaal invasieve chirurgie. Meer informatie
Beloningen Risicoanalyse + 1 meer risico
Alle risicocontroles bekijken {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Leg je gedachten, links en bedrijfsverhaal vast
Microbot Medical Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Microbot Medical Historische aandelenkoersen Huidige aandelenkoers US$2.15 52 Week Hoogtepunt US$3.38 52 Week Laag US$0.82 Bèta 1.51 1 maand verandering 20.79% 3 maanden verandering 126.32% 1 Jaar Verandering 77.69% 3 jaar verandering -63.50% 5 jaar verandering -76.73% Verandering sinds IPO -98.59%
Recent nieuws en updates Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $13.000006 million. Feb 12
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $13.000006 million. Feb 11
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $13.000006 million. Feb 10
Insufficient new directors Feb 02
Microbot Medical Inc. Appoints Ms. Michal Ahuvia to the Newly Created Role of Director of Operations Jan 21 Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 09
Meer updates bekijken Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $13.000006 million. Feb 12
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $13.000006 million. Feb 11
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $13.000006 million. Feb 10
Insufficient new directors Feb 02
Microbot Medical Inc. Appoints Ms. Michal Ahuvia to the Newly Created Role of Director of Operations Jan 21 Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 09
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $8.600009 million. Jan 08
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $7.000002 million. Jan 07
New major risk - Share price stability Jan 04
Microbot Medical Inc. Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY Dec 30
Microbot Medical Inc. Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System Dec 11
New major risk - Financial position Nov 15
Microbot Medical Inc., Annual General Meeting, Dec 17, 2024 Nov 07
Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial Oct 15
Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Oct 14
Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System Sep 17
Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center Jul 18
Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial Jul 08 Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million. Jul 02
Microbot Medical Inc. announced that it has received $1.762502 million in funding Jun 21
New major risk - Shareholder dilution Jun 06 Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million. Jun 06
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.
New minor risk - Share price stability Jun 03
Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health Apr 30
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US Feb 06
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters Jan 30
New major risk - Shareholder dilution Jan 24
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study Jan 19
Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth? Dec 30
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met Dec 29
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study Dec 07
Microbot Medical Inc. Announces Executive Changes Nov 22
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process Nov 15
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study Nov 01 Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company Oct 20
Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System Oct 18
Microbot Medical Inc., Annual General Meeting, Nov 02, 2023 Sep 06
Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth? Sep 01
Price target decreased by 60% to US$8.00 Aug 16
Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board Aug 11
Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office Jun 23
New major risk - Shareholder dilution Jun 09
Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System Jun 03
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process Jun 01
Microbot Medical Inc. announced delayed 10-Q filing May 17
Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System May 10
Price target decreased by 58% to US$8.00 May 10
Microbot Medical Inc. Announces Final Data from Its Recent Animal Study May 06
Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization May 04
Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation Dec 28
Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel Dec 10
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance Nov 19
High number of new directors Nov 16
Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System Nov 04
Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board Nov 01
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System Oct 19
Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System Oct 14
Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System Oct 12
Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop. Oct 08
Microbot Medical acquires Nitiloop, terms undisclosed Oct 07
Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment Oct 06
Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board Sep 20
Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board Sep 16
Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation Sep 13
Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System Sep 13
Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board Sep 09
Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System Sep 07
Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month Sep 03
Microbot Medical confirms GLP trial on track to begin later this month Sep 02
Microbot Medical Inc., Annual General Meeting, Sep 21, 2022 Aug 09
High number of new directors Apr 27
Will Microbot Medical (NASDAQ:MBOT) Spend Its Cash Wisely? Apr 23
High number of new directors Apr 15
Microbot Medical Inc. Announces Executive Changes Apr 07
Microbot Medical's Stryker Collaboration Makes This An Intriguing High Flier Jan 06
Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States Dec 24
Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth Dec 24
We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth Aug 27
Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology Jun 30
Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth May 12
New 90-day high: US$9.49 Feb 09
Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt Jan 29
We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth Jan 27
Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System Jan 15 Rendement voor aandeelhouders MBOT US Medical Equipment US Markt 7D 5.4% -0.2% 0.2% 1Y 77.7% 14.4% 23.1%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: MBOT overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 14.4 % opleverde.
Rendement versus markt: MBOT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 23.1 %.
Prijsvolatiliteit Is MBOT's price volatile compared to industry and market? MBOT volatility MBOT Average Weekly Movement 31.3% Medical Equipment Industry Average Movement 8.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stabiele aandelenkoers: De aandelenkoers van MBOT is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van MBOT is het afgelopen jaar gestegen van 18% naar 31%.
Over het bedrijf Microbot Medical Inc., een preklinisch bedrijf voor medische apparatuur, houdt zich bezig met onderzoek, ontwerp en ontwikkeling van endoluminale chirurgische robotapparaten gericht op minimaal invasieve chirurgie. Het bedrijf biedt LIBERTY, een endovasculair robotchirurgisch systeem waarmee artsen een kathetergebaseerde procedure kunnen uitvoeren buiten het katheterisatielaboratorium, en stralingsblootstelling, fysieke belasting en het risico op kruisbesmetting kunnen vermijden voor gebruik in cardiovasculaire, perifere en neurovasculaire ruimten. Het bedrijf levert ook NovaCross, een intellectueel eigendom en technologie op het gebied van intraluminale revascularisatiehulpmiddelen met verankeringsmechanisme en geïntegreerde microkatheter.
Meer tonen Microbot Medical Inc. Samenvatting Hoe verhouden de winst en inkomsten van Microbot Medical zich tot de beurswaarde? MBOT fundamentele statistieken Marktkapitalisatie US$34.37m Inkomsten(TTM ) -US$11.20m Inkomsten(TTM ) n/a
0.0x P/S-verhouding
-3.2x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) MBOT resultatenrekening (TTM ) Inkomsten US$0 Kosten van inkomsten US$0 Brutowinst US$0 Overige uitgaven US$11.21m Inkomsten -US$11.20m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.66 Brutomarge 0.00% Nettowinstmarge 0.00% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde MBOT op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/02/12 02:24 Aandelenkoers aan het einde van de dag 2025/02/12 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten Microbot Medical Inc. wordt gevolgd door 2 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Raghuram Selvaraju H.C. Wainwright & Co. Jeffrey Cohen Ladenburg Thalmann & Company
